Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Lollinoba has officially signed with Veloce and will bring more exciting content

Lollinoba has officially signed with Veloce and will bring more exciting content

依始2024/12/03 02:29
Veloce Media Group is a decentralized gaming and sports media company whose business involves the intersection of gaming, racing, and new technologies. To elevate the meaning of fans to a new level, Veloce is a fan-integrated sports and gaming ecosystem supported by VEXT.
 
Earlier, Veloce Esports officially announced that Lorenzo Bastiani (screen name Lollinoba) has officially joined the Veloce family! This outstanding creator in the F1 Creator Series is about to bring more exciting content, from online to offline real racing experiences, which are worth looking forward to.
0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

Yen appreciation and global bond slump lead Japan GPIF to first loss in six quarters, with almost no asset allocation adjustment

According to the latest quarterly report from Japan’s Government Pension Investment Fund (GPIF), its asset allocation remained almost unchanged from its model portfolio for the three months ending in late September. However, the fund recorded a 1.7% quarterly loss during this period—the first loss in six quarters—due to a global slump in bond prices and the appreciation of the yen.

智通财经•2026/11/06 08:27

GlaxoSmithKline endorses: anti-inflammatory biotech company Rezera (RZRA.US) plans to raise $200 millions through IPO, with a valuation of $254 millions

Rezera plans to raise $200 million in its IPO on Nasdaq, with an offering price between $11 and $13. GSK intends to subscribe for up to $25 million. The mid-point valuation is $254 million, and the company focuses on oral NLRP3 inhibitors.

智通财经•2026/11/06 07:56